Skip to content
lifestyle.cosmeticsurgeryinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AbbVie Inc.
AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn’s Disease
April 27, 2026
AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
April 23, 2026
AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
April 22, 2026
AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
April 13, 2026
BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through “The Confidence Collective” for Fourth Year
April 8, 2026
Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin
April 7, 2026
Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
March 26, 2026
Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)
March 26, 2026
AbbVie Named Official Pharmaceutical Partner of Major League Baseball
March 24, 2026
U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
February 20, 2026
←
Previous Page
1
2